Anamorelin, a highly selective ghrelin receptor agonist,4 was approved in Japan in January 2021 for the treatment of cancer cachexia associated with non‐small cell lung cancer (NSCLC), gastric cancer (GC), pancreatic cancer (PC), or colorectal cancer (CRC).5 The gene discussed is GHSR; the disease is gastric cancer.